Lexology November 14, 2024
Morgan Lewis & Bockius LLP

By Jacqueline Berman, Michele Buenafe and Kathleen Sanzo (November 14, 2024, 6:41 PM EST)

The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, has prompted many in the life sciences industry to question how this political shift may affect the regulation of drugs, devices and other life sciences products by the U.S. Food and Drug Administraiton and related regulators.

While Trump has not yet articulated specific policy priorities with respect to the life sciences industry, what is clear is that the sector is positioned to see significant changes. We describe below key areas to watch as the new Trump-Vance administration takes shape.

Jacqueline Berman

New Agency Heads and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Regulations
Related Articles:
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens
PBM reform dropped in Congress' funding package
2025 and Beyond: Key Trends to Watch in Pharmacy

Share This Article